Literature DB >> 15293567

Two entities of precursor T-cell lymphoblastic leukemia/lymphoma based on radiologic and immunophenotypic findings.

Yasushi Onishi1, Yoshihiro Matsuno, Ukihide Tateishi, Akiko Miyagi Maeshima, Masahiko Kusumoto, Takashi Terauchi, Shigeru Kusumoto, Naohiro Sekiguchi, Kazuki Tanimoto, Takashi Watanabe, Yukio Kobayashi, Kensei Tobinai.   

Abstract

Precursor T-cell lymphoblastic leukemia/lymphoma (T-ALL/LBL) presents a mediastinal mass in one half of cases. Although the immunophenotypic features of T-ALL/LBL have been analyzed in several studies, few studies have been focused on the relationship between the anatomic distribution of lesions and immunophenotypic findings. We analyzed the clinicopathologic findings for 17 patients with T-ALL/LBL diagnosed since 1993 and whose radiologic findings were available. Data on 14 men and 3 women with a median age of 26 years (range, 10-61 years) were analyzed. On the basis of radiologic findings, the cases were divided into thymic type (n = 8) and nonthymic type (n = 9). Patients with the thymic type of T-ALL/LBL had a large mediastinal mass and minimal systemic lymphadenopathy only in the supradiaphragmatic region. Those with the non-thymic type had predominantly systemic lymphadenopathy that included infradiaphragmatic lesions. Expression of CD8 (6/7 versus 0/9) was more frequently found in the thymic type (P < .001), whereas expression of CD56 (0/7 versus 5/9) was more frequent in the nonthymic type (P = .034). In conclusion, T-ALL/LBL was divided into 2 entities, thymic type and nonthymic type, on the basis of radiologic findings and immunophenotypic features. Analysis of the expression of CD8 and CD56 would be useful for biologically classifying T-ALL/LBL into the 2 types. This study was performed in a single institution, was retrospective, and had a limited number of patients; multicenter confirmatory studies are warranted.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15293567     DOI: 10.1532/ijh97.04061

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  29 in total

1.  Lymphoblastic lymphoma expressing CD56 and TdT.

Authors:  S Nakamura; T Koshikawa; Y Yatabe; T Suchi
Journal:  Am J Surg Pathol       Date:  1998-01       Impact factor: 6.394

2.  Lymphoblastic lymphoma: an immunophenotype study of 26 cases with comparison to T cell acute lymphoblastic leukemia.

Authors:  L M Weiss; J M Bindl; V J Picozzi; M P Link; R A Warnke
Journal:  Blood       Date:  1986-02       Impact factor: 22.113

3.  Prognosis and treatment of lymphoblastic lymphoma in adults: a report on 80 patients.

Authors:  P Morel; E Lepage; P Brice; B Dupriez; M F D'Agay; P Fenaux; B Gosselin; F Bauters; C Gisselbrecht
Journal:  J Clin Oncol       Date:  1992-07       Impact factor: 44.544

4.  Lymphoblastic lymphoma with convoluted nuclei. A report of 19 cases.

Authors:  C Baldit; M Trojani; H Eghbali; G Hoerni-Simon; B Hoerni
Journal:  Oncology       Date:  1984       Impact factor: 2.935

5.  Thymic lymphoblastic lymphoma of committed natural killer cell precursor origin: a case report.

Authors:  R Ichinohasama; K Endoh; K Ishizawa; M Okuda; J Kameoka; K Meguro; J Myers; M E Kadin; S Mori; T Sawai
Journal:  Cancer       Date:  1996-06-15       Impact factor: 6.860

6.  Lymphoblastic lymphoma in adults.

Authors:  R A Streuli; Y Kaneko; D Variakojis; A Kinnealey; H M Golomb; J D Rowley
Journal:  Cancer       Date:  1981-05-15       Impact factor: 6.860

7.  A morphologic study of childhood lymphoma of the lymphoblastic type. The pediatric Oncology Group experience.

Authors:  R C Griffith; D R Kelly; B N Nathwani; J J Shuster; S B Murphy; E Hvizdala; M P Sullivan; C W Berard
Journal:  Cancer       Date:  1987-03-15       Impact factor: 6.860

8.  Antigenically defined subgroups of lymphoblastic lymphoma. Relationship to clinical presentation and biologic behavior.

Authors:  K Sheibani; B N Nathwani; C D Winberg; J S Burke; W G Swartz; D Blayney; S van de Velde; L R Hill; H Rappaport
Journal:  Cancer       Date:  1987-07-15       Impact factor: 6.860

9.  Clinicopathologic study of CD56 (NCAM)-positive angiocentric lymphoma occurring in sites other than the upper and lower respiratory tract.

Authors:  S Nakamura; T Suchi; T Koshikawa; K Kitoh; K Koike; H Komatsu; S Iida; Y Kagami; M Ogura; E Katoh
Journal:  Am J Surg Pathol       Date:  1995-03       Impact factor: 6.394

10.  Acute lymphoblastic leukemia of NK-cell lineage: responses to IL-2.

Authors:  S J Pirruccello; M S Bicak; B G Gordon; K Gajl-Peczalska; D J Gnarra; P F Coccia
Journal:  Leuk Res       Date:  1989       Impact factor: 3.156

View more
  3 in total

1.  CD56 expression in T-cell acute lymphoblastic leukemia is associated with non-thymic phenotype and resistance to induction therapy but no inferior survival after risk-adapted therapy.

Authors:  Lars Fischer; Nicola Gökbuget; Stefan Schwartz; Thomas Burmeister; Harald Rieder; Monika Brüggemann; Dieter Hoelzer; Eckhard Thiel
Journal:  Haematologica       Date:  2008-12-23       Impact factor: 9.941

2.  Changes in mouse thymus and spleen after return from the STS-135 mission in space.

Authors:  Daila S Gridley; Xiao Wen Mao; Louis S Stodieck; Virginia L Ferguson; Ted A Bateman; Maria Moldovan; Christopher E Cunningham; Tamako A Jones; Jerry M Slater; Michael J Pecaut
Journal:  PLoS One       Date:  2013-09-19       Impact factor: 3.240

3.  Immature T cell neoplasms in three young cattle.

Authors:  Rie Yokota; Kenshi Sato; Yoshihiro Wada; Yoshiharu Ishikawa; Koichi Kadota
Journal:  J Vet Med Sci       Date:  2015-07-23       Impact factor: 1.267

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.